Dyne Therapeutics surges following initial data from ACHIEVE and DELIVER trials Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Dyne Therapeutics (DYN) up 45% after announcing initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping
- PGT Innovations (PGTI) up 4% after disclosing an unsolicited takeover proposal from Miter Brands to acquire all outstanding shares of PGT Innovations' common stock for $41.50 per share in cash
- Regulus (RGLS) up 3% after completing enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD
- Bloomin' Brands (BLMN) up 3% after appointing Dave George and Jon Sagal, partner at Starboard Value together with certain of its affiliates, to the company's board of directors, effective immediately
LOWER -
- Esperion (ESPR) down 15% after the company and Daiichi Sankyo Europe (DSNKY) announced a $125M amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products
- Mercury Systems (MRCY) down 2% after Jefferies downgraded the stock to Underperform
- Ambarella (AMBA) down 4% after Wells Fargo downgraded shares to Equal Weight
- Wendy's (WEN) down 1% after Barclays downgraded the stock to Equal Weight
- Apple (AAPL) down 1% after Barclays downgraded shares to Underweight with a price target of $160, down from $161
Symbols:
DYN BLMN PGTI ESPR MRCY AMBA WEN RGLS AAPL Keywords: Fly Intel, Wall Street, Top Stories, Stocks